ArticleAnnals of intensive care2025
Outcomes of carbapenem-resistant Acinetobacter baumannii bloodstream infections in intensive care units and prognostic effect of different antimicrobial regimens.
Article in Annals of intensive care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Ceftazidime-Avibactam Versus Colistin-Based Regimens for Carbapenem-Resistant Enterobacterales Bloodstream Infections: A Six-Year Retrospective Cohort and 30-Day Mortality Analysis.Microorganisms · 2026Article
- Clinical Outcomes of Pandrug-Resistant Versus Carbapenem-Resistant, Colistin-SusceptibleAntibiotics (Basel, Switzerland) · 2026Article
- Effectiveness of conventional antimicrobial agents against carbapenem resistant non-carbapenem β-lactams susceptible Pseudomonas aeruginosa infection in critically ill patients: a multicentre retrospective study.BMC infectious diseases · 2026Observational
- Association of Once-Daily MALDI-TOF MS Identification with Antibiotic Appropriateness and First-Modification Patterns in Emergency Department Bacteremia: A Retrospective Before-After Cohort Study.Antibiotics (Basel, Switzerland) · 2026Article
- Six Years ofAntibiotics (Basel, Switzerland) · 2026Article
- Article
- Treating Extensively Drug-ResistantPathogens (Basel, Switzerland) · 2026Review
- Recent Advances and Future Perspectives in the Detection of Carbapenem-ResistantInfection and drug resistance · 2026Review
- Caerin 1.1/1.9 peptides controlFrontiers in microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCarbapenem-resistant Acinetobacter baumannii (CRAB) poses a significant global threat due to limited therapeutic options and high rates of associated mortality. CRAB-related bloodstream infections (BSIs) in intensive care units (ICUs) represent a major clinical challenge. This study aimed to investigate the clinical outcomes of CRAB-BSIs in ICU settings and evaluate the prognostic effect of different antimicrobial regimens.
methodsThis multicenter, retrospective observational study was conducted at five medical centers in Taiwan and included 393 critically ill patients with CRAB-BSIs between January 2015 and December 2019. Clinical and microbiological outcomes were analyzed. Multivariable regression analysis was used to identify independent prognostic factors for day-28 mortality.
resultsThe most common causes of CRAB-BSIs were pneumonia (42.5%) and catheter-related infections (38.7%). The day-28 mortality rate following BSI onset was 56.5%. A higher sequential organ failure assessment (SOFA) score independently predicted increased day-28 mortality. Colistin-based therapy was associated with improved survival outcomes in the original (adjusted hazard ratio [aHR], 0.56; 95% confidence intervals (CI), 0.35-0.88) and time-window bias-adjusted (aHR, 0.59; 95% CI, 0.37-0.94) cohorts. Among patients with pneumonia-related CRAB-BSIs, colistin-based therapy did not significantly improve day-28 survival, whereas sulbactam-based therapy showed survival benefit (aHR, 0.37; 95% CI, 0.15-0.91). Neither carbapenem-based nor tigecycline-based therapies demonstrated a mortality benefit on day 28.
conclusionCRAB-BSIs are associated with high mortality in critically ill patients. In settings where novel antibiotics are not available, colistin-based therapy was associated with improved clinical outcomes. Among patients with pneumonia-related CRAB-BSIs, sulbactam-based therapy was associated with lower mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.